Pasithea Therapeutics (KTTA) Net Cash Flow (2021 - 2024)
Historic Net Cash Flow for Pasithea Therapeutics (KTTA) over the last 4 years, with Q4 2024 value amounting to -$2.5 million.
- Pasithea Therapeutics' Net Cash Flow rose 2386.63% to -$2.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$13.9 million, marking a year-over-year increase of 1529.49%. This contributed to the annual value of -$9.4 million for FY2024, which is 4287.52% up from last year.
- As of Q4 2024, Pasithea Therapeutics' Net Cash Flow stood at -$2.5 million, which was up 2386.63% from -$3.1 million recorded in Q3 2024.
- In the past 5 years, Pasithea Therapeutics' Net Cash Flow ranged from a high of $32.4 million in Q4 2021 and a low of -$7.0 million during Q3 2023
- Over the past 4 years, Pasithea Therapeutics' median Net Cash Flow value was -$3.1 million (recorded in 2023), while the average stood at $508473.9.
- Its Net Cash Flow has fluctuated over the past 5 years, first plummeted by 36044.72% in 2022, then skyrocketed by 5572.22% in 2024.
- Quarter analysis of 4 years shows Pasithea Therapeutics' Net Cash Flow stood at $32.4 million in 2021, then tumbled by 117.06% to -$5.5 million in 2022, then skyrocketed by 41.39% to -$3.2 million in 2023, then grew by 23.87% to -$2.5 million in 2024.
- Its last three reported values are -$2.5 million in Q4 2024, -$3.1 million for Q3 2024, and -$4.0 million during Q2 2024.